These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 9797864

  • 21. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.
    Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA.
    Cancer Gene Ther; 1994 Mar; 1(1):5-13. PubMed ID: 7621238
    [Abstract] [Full Text] [Related]

  • 22. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector.
    Lee MG, Abina MA, Haddada H, Perricaudet M.
    Gene Ther; 1995 Jun; 2(4):256-62. PubMed ID: 7552985
    [Abstract] [Full Text] [Related]

  • 23. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
    Wright P, Zheng C, Moyana T, Xiang J.
    Cancer Gene Ther; 1998 Jun; 5(6):371-9. PubMed ID: 9917092
    [Abstract] [Full Text] [Related]

  • 24. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
    Ichikura H, Eto M, Ueno H, Harada M, Takayama K, Tokuda N, Tatsugami K, Naito S.
    Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
    [Abstract] [Full Text] [Related]

  • 25. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
    Grace MJ, Xie L, Musco ML, Cui S, Gurnani M, DiGiacomo R, Chang A, Indelicato S, Syed J, Johnson R, Nielsen LL.
    Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer.
    von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM.
    Gynecol Oncol; 1998 Jun; 69(3):197-204. PubMed ID: 9648587
    [Abstract] [Full Text] [Related]

  • 28. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products.
    Gahéry-Ségard H, Molinier-Frenkel V, Le Boulaire C, Saulnier P, Opolon P, Lengagne R, Gautier E, Le Cesne A, Zitvogel L, Venet A, Schatz C, Courtney M, Le Chevalier T, Tursz T, Guillet JG, Farace F.
    J Clin Invest; 1997 Nov 01; 100(9):2218-26. PubMed ID: 9410899
    [Abstract] [Full Text] [Related]

  • 29. [Intravenous delivery of cationic liposomes conjugation to recombinant adenoviral vectors containing human endostatin gene inhibits ovarian cancer growth in nude mice].
    Wang L, Yang L, Wu YK, Zhao X, Wei YQ, Li W, Tian Q.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar 01; 40(2):190-4. PubMed ID: 19462887
    [Abstract] [Full Text] [Related]

  • 30. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
    Wang L, Qi X, Sun Y, Liang L, Ju D.
    Cancer Gene Ther; 2002 Oct 01; 9(10):819-24. PubMed ID: 12224022
    [Abstract] [Full Text] [Related]

  • 31. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus.
    Anderson SC, Johnson DE, Harris MP, Engler H, Hancock W, Huang WM, Wills KN, Gregory RJ, Sutjipto S, Wen SF, Lofgren S, Shepard HM, Maneval DC.
    Clin Cancer Res; 1998 Jul 01; 4(7):1649-59. PubMed ID: 9676839
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration.
    Parks R, Evelegh C, Graham F.
    Gene Ther; 1999 Sep 01; 6(9):1565-73. PubMed ID: 10490766
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity.
    Milas M, Yu D, Lang A, Ge T, Feig B, El-Naggar AK, Pollock RE.
    Cancer Gene Ther; 2000 Mar 01; 7(3):422-9. PubMed ID: 10766348
    [Abstract] [Full Text] [Related]

  • 37. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model.
    Tsai V, Johnson DE, Rahman A, Wen SF, LaFace D, Philopena J, Nery J, Zepeda M, Maneval DC, Demers GW, Ralston R.
    Clin Cancer Res; 2004 Nov 01; 10(21):7199-206. PubMed ID: 15534093
    [Abstract] [Full Text] [Related]

  • 38. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53.
    Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S.
    Gene Ther; 2000 Dec 01; 7(24):2071-9. PubMed ID: 11223987
    [Abstract] [Full Text] [Related]

  • 39. [Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer].
    Yang Q, Yang G, Wei L, Jia F, Wu M, Guo Y.
    Zhonghua Yi Xue Za Zhi; 2002 Jun 10; 82(11):775-9. PubMed ID: 12126551
    [Abstract] [Full Text] [Related]

  • 40. Use of protamine to augment adenovirus-mediated cancer gene therapy.
    Lanuti M, Kouri CE, Force S, Chang M, Amin K, Xu K, Blair I, Kaiser L, Albelda S.
    Gene Ther; 1999 Sep 10; 6(9):1600-10. PubMed ID: 10490770
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.